Advertisement

Topics

Merck Confirms Forecast for Organic Performance in 2019

10:00 EDT 14 May 2019 | Bionity

Merck significantly increased net sales in the first quarter of 2019, primarily on an organic basis. By contrast, EBITDA pre saw a slight organic decline and was adversely impacted by the absence of positive one-time effects from the previous year. Merck confirmed its full-year forecast for organic ...

Original Article: Merck Confirms Forecast for Organic Performance in 2019

NEXT ARTICLE

More From BioPortfolio on "Merck Confirms Forecast for Organic Performance in 2019"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...